Literature DB >> 19889076

Host single nucleotide polymorphisms of MMP-9 -1562/TIMP-1 372 have gender differences in the risk of gastric intestinal metaplasia after Helicobacter pylori infection.

Kuei-Hsiang Hung1, Hunt-Wen Hung, Hsiao-Bai Yang, Cheng-Chan Lu, Jiunn-Jong Wu, Bor-Shyang Sheu.   

Abstract

BACKGROUND: Helicobacter pylori infection causes chronic gastric inflammation and intestinal metaplasia (IM), related with deregulation of Wnt pathway and over-expressions of COX-2, matrix metalloproteinase (MMP), and tissue inhibitors of matrix metalloproteinase (TIMP). We thus test the host genomic predispositions related to the risk of IM after H. pylori infection.
METHODS: We enrolled 296 H. pylori-infected patients to provide gastric biopsies for histology and genomic DNA for genotypes of single nucleotide polymorphisms (SNPs), including APC, COX-2, IL-1B, IL-1RN, IL-10, MMP-2, MMP-9, TIMP-1, and TIMP-2 determined by sequence specific oligonucleotide probe, sequence specific primers, restriction fragment length polymorphism, or real-time polymerase chain reaction.
RESULTS: There was no association between the presence of IM and SNPs in APC, COX-2, IL-1B, IL-1RN, IL-10, MMP-2, and TIMP-2. The risk of IM was increased up to 2.29-folds in males with TIMP-1 372 C, and 3.03-fold in females with T carrier (p < .05). The combination genotype of MMP-9 -1562/TIMP-1 372 as CC/C and CT/T in males had a 4.5-fold increased risk of IM, as compared to CC/T (p < .05). Females with such combination genotype as CC/T-carrier had a 3-fold risk of IM than males with CC/T (p < .05). In contrast, males' combination genotype as CC/C had a 3-fold risk of IM than females with CC/CC (p = .05).
CONCLUSIONS: The host MMP-9 -1562/TIMP-1 372 SNPs had gender differences in the risk of IM after H. pylori infection, and could possibly serve as a host factor to identify the risk group harboring gastric precancerous changes after H. pylori infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19889076     DOI: 10.1111/j.1523-5378.2009.00717.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  7 in total

1.  Genomic single nucleotide polymorphisms in the offspring of gastric cancer patients predispose to spasmolytic polypeptide-expressing metaplasia after H. pylori infection.

Authors:  Yu-Ching Tsai; Wei-Hsin Hsiao; Sheng-Hsiang Lin; Hsiao-Bai Yang; Hsiu-Chi Cheng; Wei-Lun Chang; Cheng-Chan Lu; Bor-Shyang Sheu
Journal:  J Biomed Sci       Date:  2015-02-21       Impact factor: 8.410

Review 2.  The Wnt Blows: On the Functional Role of Wnt Signaling in Mycobacterium tuberculosis Infection and Beyond.

Authors:  Julius Brandenburg; Norbert Reiling
Journal:  Front Immunol       Date:  2016-12-26       Impact factor: 7.561

3.  Andrographolide Inhibits Proliferation and Metastasis of SGC7901 Gastric Cancer Cells.

Authors:  Lei Dai; Gang Wang; Wensheng Pan
Journal:  Biomed Res Int       Date:  2017-01-18       Impact factor: 3.411

Review 4.  Proteolysis in Helicobacter pylori-Induced Gastric Cancer.

Authors:  Gernot Posselt; Jean E Crabtree; Silja Wessler
Journal:  Toxins (Basel)       Date:  2017-04-11       Impact factor: 4.546

5.  The 372 T/C genetic polymorphism of TIMP-1 is associated with serum levels of TIMP-1 and survival in patients with severe sepsis.

Authors:  Leonardo Lorente; Mar Martín; Fátima Plasencia; Jordi Solé-Violán; José Blanquer; Lorenzo Labarta; César Díaz; Juan María Borreguero-León; Alejandro Jiménez; José Antonio Páramo; Josune Orbe; José A Rodríguez; Eduardo Salido
Journal:  Crit Care       Date:  2013-05-25       Impact factor: 9.097

6.  TIMP-1 gene polymorphism: are genetics able to predict outcome of septic patients?

Authors:  Michael Behnes; Thomas Bertsch; Ursula Hoffmann
Journal:  Crit Care       Date:  2013-07-17       Impact factor: 9.097

Review 7.  Precision Medicine Approaches to Prevent Gastric Cancer.

Authors:  Juntaro Matsuzaki; Hitoshi Tsugawa; Hidekazu Suzuki
Journal:  Gut Liver       Date:  2021-01-15       Impact factor: 4.519

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.